AACR logo

More articles from Non-Checkpoint Immunotherapies

Abstract IA24: New frontiers in oncolytic virus therapy
David M. Reese

Cancer Immunology Research Nov 2016, 4 (11 Supplement) IA24; DOI: 10.1158/2326-6066.IMM2016-IA24
Abstract PR10: Small-molecule inhibitors of CD73 promote activation of human CD8+ T cells and have profound effects on tumor growth and immune parameters in experimental tumors
Juan C. Jaen, Jay P. Powers, Ada Chen, Manmohan R. Leleti, Jarek Kalisiak, Ulrike Schindler, Joanne Bl Tan, Steve Young, Shin-Heng Chiou, Laurent Debien

Cancer Immunology Research Nov 2016, 4 (11 Supplement) PR10; DOI: 10.1158/2326-6066.IMM2016-PR10
Abstract PR11: Neo-antigen landscape dynamics during human melanoma-T cell interactions
Els M.E. Verdegaal, Noel de Miranda, Marten Visser, Tom Harryvan, Marit van Buuren, Rikke Andersen, Sine Hadrup, Caroline van der Minne, Remko Schotte, Hergen Spits, John Haanen, Ellen Kapiteijn, Ton Schumacher, Sjoerd H. Van Der Burg

Cancer Immunology Research Nov 2016, 4 (11 Supplement) PR11; DOI: 10.1158/2326-6066.IMM2016-PR11
Abstract IA25: Synergistic innate and adaptive integrin-targeted immunotherapy
Karl Dane Wittrup

Cancer Immunology Research Nov 2016, 4 (11 Supplement) IA25; DOI: 10.1158/2326-6066.IMM2016-IA25
Abstract IA23: Microenvironmental regulation of antitumor immune responses: A lesson from fibroblastic cells
Viviana Cremasco, Angelo Grauel, Michael Wu, Jillian Astarita, Matthew Woodruff, Zohreh Amoozgar, Lotte Spel, Flavian Brown, Michael Carroll, Kenzie MacIsaac, Glenn Dranoff, Shannon Turley

Cancer Immunology Research Nov 2016, 4 (11 Supplement) IA23; DOI: 10.1158/2326-6066.IMM2016-IA23
Abstract B063: Oncolytic adenoviruses armed with tumor necrosis factor alpha and interleukin-2 enable successful adoptive T cell therapy of solid tumors
Mikko Siurala, Riikka Havunen, João Santos, Siri Tähtinen, Dipongkor Saha, Markus Vähä-Koskela, Michael Behr, Dirk M. Nettelbeck, Anja Ehrhardt, Suvi Parviainen, Akseli Hemminki

Cancer Immunology Research Nov 2016, 4 (11 Supplement) B063; DOI: 10.1158/2326-6066.IMM2016-B063
Abstract B042: Potent and selective small molecule USP7 inhibitors for cancer immunotherapy
Suresh Kumar, Jian Wu, Liqing Wang, Jack Wang, Ivan Sokirniy, Hui Wang, Glen Fegley, Joseph Weinstock, Michael Mattern, Wayne W. Hancock

Cancer Immunology Research Nov 2016, 4 (11 Supplement) B042; DOI: 10.1158/2326-6066.IMM2016-B042
Abstract B043: Systems pharmacology modeling of anti-CD20/CD3 T-cell dependent bispecific antibody and its application to clinical trial design
Iraj Hosseini, Kapil Gadkar, Eric Stefanich, Chi-Chung Li, Laura Sun, Yu-Waye Chu, Saroja Ramanujan

Cancer Immunology Research Nov 2016, 4 (11 Supplement) B043; DOI: 10.1158/2326-6066.IMM2016-B043
Abstract B046: Therapeutic mechanisms of anti-4-1BB antibodies in cancer: agonism versus regulatory T cell depletion
Marcus Remer, Anne Rogel, Sarah Buchan, Peter W.M. Johnson, Aymen Al-Shamkhani

Cancer Immunology Research Nov 2016, 4 (11 Supplement) B046; DOI: 10.1158/2326-6066.IMM2016-B046
Abstract B053: Characterizing the effects of the DNA methylation inhibitor 5-AZA-CdR during CD8 T cell expansion
Helen Loo Yau

Cancer Immunology Research Nov 2016, 4 (11 Supplement) B053; DOI: 10.1158/2326-6066.IMM2016-B053

Main menu

User menu

Search

More articles from Non-Checkpoint Immunotherapies

Pages

Articles

Info for

About Cancer Immunology Research